15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Q32 Bio Inc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. The target range is very wide, $14.00 to $66.00 (about 4.7x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $38.00 sits 225% above the current $11.68. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.29 next quarter toward $-1.02 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Strong Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Q32 Bio Inc.
As of Sep, 6 of 6 firms rate QTTB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
QTTB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.29
Range $-0.36 – $-0.23 · 6 analysts · -106% YoY
Next period, 6 analysts expect Q32 Bio Inc to earn $-0.29 a share (range $-0.36 – $-0.23), versus $4.58 a year earlier. Full-year consensus is $-1.13, growing to $-1.02 the year after.
REVENUE · NEXT QUARTER
$400.0K
Range $0 – $2.0M · 6 analysts · -99% YoY
Revenue is expected to reach $400.0K (range $0 – $2.0M), -99.3% year-over-year. Full-year consensus is $400.0K, rising to $1.0M next year.
Top analysts covering Q32 Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on QTTB.
#1
Yatin Suneja
Guggenheim · Rank #21
Hold
No targeton QTTB
Overall win rate
53%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #291
Buy
$36.00+208.4% to target
Overall win rate
34%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #360
Buy
$40.00+242.6% to target
Overall win rate
33%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #390
Buy
$66.00+465.3% to target
Overall win rate
35%
+ Follow
#5
ED
Etzer Darout
BMO Capital
Hold
$3.00-74.3% to target
Coverage
—
+ Follow
QTTB stock forecast FAQ
What is QTTB's average 12-month price target?+
The 5 analysts with a live target average $38.00 for Q32 Bio Inc over the next 12 months, ranging from a $66.00 high to a $14.00 low.
Is QTTB stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for QTTB?+
The Street-high target is $66.00 (Wells Fargo), and the Street-low is $14.00 (Mizuho). The average of all 5 active targets is $38.00.
How many Wall Street analysts cover QTTB?+
6 analysts have an active rating on Q32 Bio Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering QTTB?+
Among analysts who currently cover QTTB, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Hold.
What is Q32 Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-0.29 per share (range $-0.36 – $-0.23) across 6 analysts. Full-year EPS is projected at $-1.13, rising to $-1.02 the following year.
How much revenue is Q32 Bio Inc expected to report next quarter?+
Consensus revenue is $400.0K (range $0 – $2.0M). Full-year revenue is projected at $400.0K, growing to $1.0M next year.
Have analysts been upgrading or downgrading QTTB lately?+
As of Sep, 6 of 6 firms rate QTTB a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their QTTB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
